Is Your Paper Ready for IJBM? The Biological Macromolecule Standard

I've seen a pattern in what gets through versus what doesn't at this journal, and it comes down to three questions editors seem to ask during triage.

Is the macromolecule the real focus? This sounds obvious but it's the number one scope mismatch. A paper about a starch-based hydrogel for wound healing where 80% of the results section covers cell viability and animal models isn't an IJBM paper. That's a biomaterials paper. IJBM wants to know about the starch: its molecular weight distribution, its branching architecture, how modification altered its chain conformation, and why those structural changes affect gel behavior. The biology can be there, but the macromolecular science has to drive the narrative.

Is there structural characterization? IJBM editors expect serious characterization of the macromolecule. FTIR alone won't cut it. They want to see a combination of techniques that actually tells the structural story: NMR for polysaccharide substitution patterns, circular dichroism or SAXS for protein conformational work, GPC/SEC for molecular weight distributions, XRD for crystallinity. If your characterization section is two paragraphs with FTIR and TGA, the paper isn't ready.

Does the paper connect structure to function? This is the editorial philosophy that separates IJBM from lower-tier polymer journals. It's not enough to make a modified cellulose and show it absorbs a dye. You need to explain which structural features drive the adsorption, preferably with evidence beyond just correlation. Papers that report "we modified X and it performed better" without a mechanistic link between modification and performance don't clear the bar here.

IJBM's scope is broader than most people realize, but it has boundaries that aren't always obvious from the title.

Proteins and enzymes: Yes, but with conditions. IJBM publishes protein structure-function work, enzyme immobilization studies, and protein-based materials. It doesn't publish clinical biochemistry or papers where the protein is just a biomarker in a diagnostic assay. If you're studying how a protein folds, assembles, or functions as a material, you're in scope. If you're measuring protein levels in patient serum, you aren't.

Polysaccharides and their derivatives: This is IJBM's heartland. Chitosan, cellulose, starch, alginate, hyaluronic acid, pectin, dextran. Both fundamental characterization and application studies are welcome, but application papers need that structure-function connection mentioned above.

Nucleic acids: Yes, though this category gets fewer submissions than proteins or polysaccharides. DNA/RNA structural studies, aptamer design, and nucleic acid-based materials fit well here.

Lignin: Increasingly common and increasingly welcome. IJBM has become one of the go-to journals for lignin valorization and lignin-based materials work.

Synthetic polymers: This is where authors get burned. IJBM doesn't publish work on PLGA, PEG, polyurethane, or other purely synthetic polymers unless they're grafted onto or blended with a biological macromolecule and the biological macromolecule component is the focus. A PEGylated chitosan paper where 70% of the discussion is about PEG behavior isn't going to work.

Based on common rejection patterns, here's what to watch for before you submit.

1. The "application-heavy, characterization-light" paper. You've made a chitosan film and tested it for food packaging. You've got tensile strength, water vapor permeability, oxygen barrier properties, and antimicrobial tests. All useful data. But you've got one FTIR spectrum and a vague paragraph about "interactions between chitosan and the crosslinker." IJBM will reject this at the desk. The journal wants to understand the macromolecular structure behind the performance. Without that, your paper belongs in a packaging or food science journal.

2. The scope mismatch disguised as interdisciplinary work. A paper titled "Protein-loaded nanoparticles for cancer therapy" where the protein is bovine serum albumin used as a model drug and the actual work is about the PLGA nanoparticle. The macromolecule here is window dressing. Editors spot this instantly.

3. Review articles that don't add a framework. IJBM publishes reviews, and they receive a lot of review submissions. But "Chitosan in biomedical applications: a review" isn't going to make it if it's just a chronological summary of published papers. IJBM reviews need a critical angle, a classification scheme, or a forward-looking analysis that gives readers something they couldn't get from searching PubMed themselves.

4. Incomplete molecular weight data. For polysaccharide and protein papers, not reporting molecular weight (and ideally polydispersity) is a red flag. Reviewers consistently ask for it, and editors have started screening for it. If you can't run GPC, at least provide viscosity-average molecular weight or SDS-PAGE data.

5. Ignoring recent IJBM literature. The journal publishes 5,000+ papers per year. If your citation list doesn't include any recent IJBM papers on your topic, it signals that you haven't done your homework on where the field stands in this specific journal. Editors notice.

IJBM follows standard Elsevier formatting, but here's what I've noticed about papers that move smoothly through review.

Graphical abstract: Required, and it matters more than you'd think at a high-volume journal. Editors use it for a fast visual triage. A clear schematic showing your macromolecule, the modification or interaction you studied, and the outcome works best. Don't cram six panels into it.

Introduction: Keep it to 1.5-2 pages. State the gap in macromolecular understanding, not just the application gap. "There aren't enough chitosan-based wound dressings" isn't a gap. "The relationship between chitosan's degree of deacetylation and its film-forming behavior under physiological conditions isn't well understood" is.

Characterization before application. Structure your results so that you've fully characterized your macromolecule before presenting any application data. Papers that jump straight to performance testing without establishing what the material actually looks like at the molecular level are a common revision trigger.

Word count: Most published IJBM articles run 5,000-8,000 words. Reviews go longer. The journal doesn't impose a strict cap, but papers pushing past 10,000 words need to justify the length.

Once you're past the desk, IJBM assigns 2-3 reviewers. The single-blind review means they'll know who you are, which cuts both ways. Established groups in the macromolecule field tend to get faster, more engaged reviews. Newcomers sometimes face tougher scrutiny, which makes strong characterization data even more important for early-career researchers.

Revision requests are the most common outcome for papers that reach review. Expect reviewers to ask for additional characterization data, more controls, or a deeper explanation of structure-function relationships. The revision window is typically 30-60 days for minor revisions and 60-90 days for major ones.

A realistic timeline for an accepted paper:

• Desk decision: 2-3 weeks
• First review cycle: 2-4 months
• Revision and resubmission: 1-2 months
• Second review (if needed): 3-6 weeks
• Production to publication: 2-4 weeks
• Total: 4-8 months

IJBM's APC of ~$3,800 for gold open access is mid-range for Elsevier. You don't have to go open access; subscription-based publication costs nothing. If your funder mandates open access (Plan S, NIH, UKRI), check whether your institution has an Elsevier read-and-publish agreement that covers the fee. Many universities do, and it's worth the ten minutes it takes to ask your library before budgeting $3,800 out of your grant.

Green open access (self-archiving your accepted manuscript in an institutional repository after a 24-month embargo) is also permitted under Elsevier's standard policy.